Pharmacokinetic (PK) guided optimization of 5-fluorouracil (5-FU) dosing in the treatment of patients with colorectal cancer (CRC)

被引：0
|
作者：
Goal, Gaurav
Chu, Edward
Sun, Min
Meisner, Dennis James
Lee, James J.
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[2] UPMC Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14561
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell
    Buse Ardıl
    Mehlika Alper
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 1109 - 1123
  • [22] Predictive profiling of 5-fluorouracil (5-FU) resistance in metastatic colorectal cancer (mCRC).
    Ichikawa, W
    Takahashi, T
    Suto, K
    Okayama, Y
    Toda, E
    Oka, T
    Okayama, S
    Hirayama, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 261S - 261S
  • [23] COMPARISON OF TREATMENT OF METASTATIC GASTROINTESTINAL CANCER WITH 5-FLUOROURACIL (5-FU) TO A COMBINATION OF 5-FU WITH CYTOSINE-ARABINOSIDE
    GAILANI, S
    HOLLAND, JF
    BURNINGHAM, R
    LEONE, L
    LARSEN, V
    FALKSON, G
    CANCER, 1972, 29 (05) : 1308 - +
  • [24] VARIATION IN PHARMACOKINETIC DISPOSITION OF 5-FLUOROURACIL (5-FU) IN CANCER-PATIENTS AFTER A SINGLE INTRAVENOUS DOSE
    SITAR, DS
    THIRLWELL, MP
    MANSELL, PW
    RUEDY, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 323 - 323
  • [25] TREATMENT OF EXPERIMENTAL ACUTE PANCREATITIS WITH 5-FLUOROURACIL (5-FU)
    JOHNSON, RM
    BARONE, RM
    NEWSON, BL
    DASGUPTA, TK
    NYHUS, LM
    AMERICAN JOURNAL OF SURGERY, 1973, 125 (02): : 211 - 222
  • [26] METABOLISM OF 5-FLUOROURACIL (5-FU) IN HUMAN GASTROINTESTINAL CANCER
    BERNE, M
    ALMERSJO, O
    GUSTAVSSON, B
    ACTA CHIRURGICA SCANDINAVICA, 1983, : 31 - 31
  • [27] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [28] Phase I and pharmacokinetic (PK) study of Tomudex (TOM) plus 5-fluorouracil (5-FU) and levofolinic acid (LFA) in advanced head and neck and colorectal cancer
    Caponigro, F
    Casaretti, R
    McLeod, HL
    Budillon, A
    Carteni, G
    De Vita, F
    Avallone, A
    Biglietto, M
    Tucci, A
    Morsman, J
    Barbarulo, D
    Catalano, G
    Comella, P
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 127 - 127
  • [29] RANDOMIZED TRIAL OF MELPHALAN PLUS 5-FLUOROURACIL (5-FU) VERSUS METHYL-CCNU PLUS 5-FU IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    BERMAN, R
    GILES, GR
    MALHOTRA, A
    BIRD, GG
    GAJJAR, PD
    BUNCH, GA
    HALL, R
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 457 - 459
  • [30] 5-FLUOROURACIL (5-FU) PRESENTING AS A STEMI
    Okor, Ivana
    Ghosh, Priyanka
    Bhattarai, Shraddha
    Sattur, Sudhakar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 3439 - 3439
12345